J
José Luis Zamorano
Researcher at Carlos III Health Institute
Publications - 740
Citations - 154643
José Luis Zamorano is an academic researcher from Carlos III Health Institute. The author has contributed to research in topics: Heart failure & Myocardial infarction. The author has an hindex of 105, co-authored 695 publications receiving 133396 citations. Previous affiliations of José Luis Zamorano include Hospital Clínico San Carlos & Universidad Francisco de Vitoria.
Papers
More filters
Journal ArticleDOI
Treatment of cells with n-alpha-tosyl-l-phenylalanine-chloromethyl ketone induces the proteolytic loss of STAT6 transcription factor
TL;DR: The results found suggest that the effect of TPCK was mediated by its alkylating activity, and cysteine reactive and thiol antioxidant compounds prevented the loss of STAT6 induced by T PCK.
Journal ArticleDOI
Comentarios a la guía de práctica clínica de la ESC sobre el tratamiento de las valvulopatías (versión 2012). Informe del Grupo de Trabajo del Comité de Guías de Práctica Clínica de la Sociedad Española de Cardiología
Ángel M. Alonso Gómez,José Juan Gómez de Diego,Joaquín Barba,Gonzalo Barón,Xavier Borrás,Arturo Evangelista,Ángel Luis Fernández González,Rocío García Orta,Juan José Gómez Doblas,Rosana Hernández Antolín,José María Hernández García,Patricia Mahía,José Ignacio Sáez de Ibarra,Javier Bermejo,José J. Cuenca Castillo,Miguel Angel García Fernández,Rafael García Fuster,Javier Lopez,José Eduardo López Haldón,Pilar Tornos,Alberto San Román,Marta Sitges,Isidre Vilacosta,José Luis Zamorano,Manuel Anguita,Angel Cequier,Josep Comín,Isabel Diaz-Buschmann,Ignacio Fernández Lozano,Antonio Fernández-Ortiz,Manuel Pan,Fernando Worner +31 more
TL;DR: Las guías originales traducidas al castellano se adjunta en un documento en el que se realiza una revisión crítica1 elaborado por un grupo de expertos coordinado por el CGPC (Comité de Guías de Práctica Clínica).
Journal ArticleDOI
Combining antihypertensive and antihyperlipidemic agents – optimizing cardiovascular risk factor management
TL;DR: The rationale for this combination therapy and the clinical trials that have demonstrated that these two agents can be combined without the loss of efficacy for either agent or an increase in the incidence of adverse events suggest that SPAA can play an important role in helping physicians improve the management of CV risk in their patients.
Journal Article
Perioperative mortality and long-term outcome of infective endocarditis.
Luis M Moura,José Luis Zamorano,Raúl Moreno,Carlos Almería,José Luis Rodrigo,Alexis Villate,Juan Morán,Luis Sánchez-Harguindey +7 more
TL;DR: Prosthetic valve replacement in patients with IE is associated with high perioperative mortality (17.4%).
Journal ArticleDOI
Advanced cancer is also a heart failure syndrome: a hypothesis.
Markus S. Anker,Ana Pardo Sanz,José Luis Zamorano,Mandeep R. Mehra,Javed Butler,Hanno Riess,Andrew J.S. Coats,Stefan D. Anker +7 more
TL;DR: In this paper, the authors present the hypothesis that advanced stage cancer is also a heart failure syndrome, which can develop independently of or in addition to cardiotoxic effects of anti-cancer therapies, including an increased risk of ventricular arrhythmias.